1 Vascular Surgery and Organ Transplant Unit, University Hospital of Catania, Italy.
2 Department of Surgery "Pietro Valdoni," "Sapienza" University, Rome, Italy.
J Endovasc Ther. 2018 Apr;25(2):169-177. doi: 10.1177/1526602818754862. Epub 2018 Jan 31.
To assess early and midterm outcomes of iliac branch device (IBD) implantation without an aortic stent-graft for the treatment of isolated common iliac artery aneurysm (CIAA).
From December 2006 to June 2016, 49 isolated CIAAs in 46 patients were treated solely with an IBD at 7 vascular centers. Five patients were lost to follow-up, leaving 41 male patients (mean age 72.5±7.8 years) for analysis. Mean CIAA diameter was 39.1±10.5 mm (range 25-65). Thirty-two patients (2 with bilateral CIAAs) were treated with a Cook Zenith iliac branch device; 9 patients (1 bilateral) received a Gore Excluder iliac branch endoprosthesis. Primary endpoints were technical success, survival, aneurysm exclusion, device patency, and freedom from reintervention at 1 and 5 years. Freedom from major adverse events and aneurysm shrinkage at 1 year were also assessed.
Thirty-day mortality and the IBD occlusion rate were 2.4% and 2.3%, respectively. At a mean follow-up of 40.2±33.9 months, no patient presented buttock claudication, erectile dysfunction, or bowel or spinal cord ischemia. Three patients died within 6 months after the procedure. Estimates of cumulative survival, device patency, and freedom from reintervention were 90.2%, 95.2%, and 95.7%, respectively, at 1 and 5 years. At 1 year, CIAA shrinkage ≥5 mm was recorded in 21 of 38 survivors. No evidence of endoleak, device migration, or disconnection was found on imaging follow-up.
The use of IBDs without an aortic stent-graft for isolated CIAAs resulted in excellent patency, with low morbidity and mortality. This, in conjunction with no endoleak or migration and a low reintervention rate, supports the use of isolated IBDs as a stable and durable means of endovascular reconstruction in cases with suitable anatomy. Longer follow-up and a larger cohort are needed to validate these results.
评估髂分支装置(IBD)植入术治疗孤立性髂总动脉瘤(CIAA)的早期和中期结果,该术式不使用主动脉支架移植物。
2006 年 12 月至 2016 年 6 月,7 个血管中心对 46 例 49 个孤立性 CIAAs 仅采用 IBD 进行治疗。5 例患者失访,对 41 例男性患者(平均年龄 72.5±7.8 岁)进行分析。平均 CIAA 直径为 39.1±10.5mm(范围 25-65mm)。32 例患者(双侧 CIAAs 2 例)接受 Cook Zenith 髂分支装置治疗;9 例患者(双侧 1 例)接受 Gore Excluder 髂分支内支架。主要终点为 1 年和 5 年的技术成功率、存活率、动脉瘤排除、装置通畅率和免于再干预。还评估了 1 年时免于主要不良事件和动脉瘤缩小。
30 天死亡率和 IBD 闭塞率分别为 2.4%和 2.3%。在平均 40.2±33.9 个月的随访中,没有患者出现臀肌跛行、勃起功能障碍、肠或脊髓缺血。3 例患者在手术后 6 个月内死亡。估计 1 年和 5 年的累积存活率、装置通畅率和免于再干预率分别为 90.2%、95.2%和 95.7%。在 1 年时,21 例存活患者的 CIAA 缩小≥5mm。影像学随访未发现内漏、装置迁移或分离。
对于孤立性 CIAAs,使用无主动脉支架移植物的 IBD 治疗结果极好,发病率和死亡率均较低。再加上无内漏或迁移,以及较低的再干预率,支持将孤立性 IBD 作为一种稳定且持久的血管内重建方法,用于具有合适解剖结构的病例。需要更长时间的随访和更大的队列来验证这些结果。